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Trade-offs between drug toxicity and benefit in
the multi-antibiotic resistance system underlie
optimal growth of E. coli
Kevin B Wood and Philippe Cluzel
*
Abstract
Background: Efflux is a widespread mechanism of reversible drug resistance in bacteria that can be triggered by
environmental stressors, including many classes of drugs. While such chemicals when used alone are typically toxic
to the cell, they can also induce the efflux of a broad range of agents and may therefore prove beneficial to cells in
the presence of multiple stressors. The cellular response to a combination of such chemical stressors may be
governed by a trade-off between the fitness costs due to drug toxicity and benefits mediated by inducible systems.
Unfortunately, disentangling the cost-benefit interplay using measurements of bacterial growth in response to the
competing effects of the drugs is not possible without the support of a theoretical framework.
Results: Here, we use the well-studied multiple antibiotic resistance (MAR) system in E. coli to experimentally
characterize the trade-off between drug toxicity (“cost”) and drug-induced resistance (“benefit”) mediated by efflux
pumps. Specifically, we show that the combined effects of a MAR-inducing drug and an antibiotic are governed by
a superposition of cost and benefit functions that govern these trade-offs. We find that this superposition holds for
all drug concentrations, and it therefore allows us to describe the full dose–response diagram for a drug pair using
simpler cost and benefit functions. Moreover, this framework predicts the existence of optimal growth at a non-
trivial concentration of inducer. We demonstrate that optimal growth does not coincide with maximum induction
of the mar promoter, but instead results from the interplay between drug toxicity and mar induction. Finally, we
derived and experimentally validated a general phase diagram highlighting the role of these opposing effects in
shaping the interaction between two drugs.
Conclusions: Our analysis provides a quantitative description of the MAR system and highlights the trade-off
between inducible resistance and the toxicity of the inducing agent in a multi-component environment. The results
provide a predictive framework for the combined effects of drug toxicity and induction of the MAR system that are
usually masked by bulk measurements of bacterial growth. The framework may also be useful for identifying
optimal growth conditions in more general systems where combinations of environmental cues contribute to both
transient resistance and toxicity.
Background
The resistance of bacteria to antibiotics has prompted in-
tense scientific research in the last several decades be-
cause it directly underlies the clinical treatment of
infections [1]. While a large number of studies have fo-
cused on mutation-driven resistance, recent attention
has also shifted to transient, or “inducible”, drug resist-
ance taking place on much shorter timescales [2-9]. This
transient resistance does not rely on mutations, but can
be induced by a large class of chemicals commonly
found in drugs (e.g. antibiotics and painkillers) and food
preservatives. These chemicals are typically toxic to the
cell when used alone, but they can also induce resistance
to a broad range of agents. Consequently, they may
prove beneficial to cells in the presence of multiple stres-
sors. The net effect of a combination of chemical stres-
sors can therefore be counterintuitive, because it is
governed by the interplay between inducible resistance
and drug toxicity. Such situations may arise, for example,
in the human digestive tract, where bacteria face a
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of multiple stressors, in general, have been studied for
many decades in hopes of optimizing the clinical efficacy
of combinatorial therapies [10-12]. More recently, the
effects of drug interactions on the evolution of irrevers-
ible (mutation-driven) drug resistance have also been
recognized [13-16]. Drugs that interact synergistically to
produce a strong toxic effect can accelerate the acquisition
of mutations conferring drug resistance [14]. On the other
hand, antagonistic drug pairs produce a weaker toxic effect
but can slow the acquisition of resistance [13,15]. These
results demonstrate an inherent trade-off between the tox-
icity of the drug combination and its potential to facili-
tate drug resistance [17]. They also raise an interesting
question: do trade-offs between drug toxicity and resist-
ance also play a role in inducible drug resistance? Fur-
thermore, when cells are exposed a combination of toxic
agents that potentially induce transient resistance, how
are these trade-offs related to synergy or antagonism be-
tween the given agents?
To address these questions, here we study inducible re-
sistance mediated by the MAR (multiple antibiotic re-
sistance) system. The MAR system, present in many
bacterial species, consists of an operon that confers
efflux-mediated [18-21] resistance to a broad range of anti-
biotics and can be activated by a host of chemical agents,
including analgesics and food preservatives [2-5,7-9,22-
25]. For example, in E. coli, high concentrations (5 mM) of
salicylate, a well-known analgesic, lead to an increase in
the minimum inhibitory concentration (MIC) of several
antibiotics, and this effect has been partially attributed to
the MAR system [4,26,27]. However, MIC alone masks
the distinct effects of salicylate toxicity, antibiotic tox-
icity, and induction of the MAR system (the “benefit” of
salicylate) on the growth, because it provides only an ag-
gregate measure of these effects. Therefore, the under-
lying nature of the cost-benefit interplay remains hidden.
Here we combine experiments with a simple phenom-
enological model to fully characterize a range of effects
resulting from the trade-off between drug toxicity and
the benefit mediated by efflux pumps.
Results
Experimental characterization of salicylate-induced
antibiotic resistance
To study the trade-off between drug toxicity and
induced resistance, we first measured the effects of sali-
cylate and two protein synthesis inhibitors, chloram-
phenicol and tetracycline, on cell growth. As expected,
the effect of each drug alone is to slow cell growth as
concentration increases. To quantitatively characterize
this effect, we define growth cost as the reduction in
growth rate of cells treated with one drug relative to the
growth rate of untreated cells. In general, we find that
cost functions are well-described by Hill functions with
Ki, the concentration of drug i at which cost is half
maximal, and n, the Hill coefficient (Figure 1a). This
mathematical form is consistent with standard dose–re-
sponse models [10]. In the presence of a high concen-
tration of chloramphenicol or tetracycline, however, we
find that adding salicylate can increase growth (Fig-
ure 1b, Additional file 1: Figure S1). This effect was
previously reported for a single concentration of sali-
cylate [26]; here we provide the entire non-monotonic
dependence of this suppressive effect on concentration,
allowing us to tease apart contributions of salicylate’s
cost from its benefit (below). We also performed detailed
quantitative measurements of another suppressive inter-
action between an antibiotic, chloramphenicol, but with
a different inducer, sodium benzoate (Additional file 1:
Figure S1).
Phenomenological cost-benefit model for MAR-induced
drug resistance
To quantitatively model the interplay between inducer
cost and benefit in a two-drug environment that
includes an inducer, we assume that the effects of the
two drugs, in the absence of MAR induction, are inde-
pendent in the sense that the relative growth rate of
cells in the presence of both drugs (gSA) equals the
product of individual relative growth rates of cells in
the presence of each drug alone (gSA=g S gA). This as-
sumption, known as Bliss independence [11], provides
exact results for simple situations, such as a single en-
zymatic reaction disrupted by mutually non- exclusive
inhibitors [10], in which case the effects of the drugs
are defined in terms of reaction fluxes. However, the
assumption of Bliss independence often fails for more
complex systems, and it is therefore primarily used as a
phenomenological null model for the physiological
effects of non-interacting drugs on cell proliferation or
growth [10,14,28-30].
Here, we extend the concept of Bliss independence to in-
clude drug interactions mediated by the induction of the
MAR system. Specifically, we assume that the presence of
one drug (S) provides a fitness benefit by reducing the ef-
fective concentration of the second drug (A), thereby coup-
ling the effects of the drugs. We incorporate this rescaling
and re-write the model in terms of the combined growth
cost, CSA (by definition 1- gSA)t oa r r i v ea t
CSA ¼ fA eff

þ gs ðÞ  fA eff

gs ðÞ ð1Þ
where f(A) and g(S) are the growth costs of drugs alone
(Figure 1a). Equation 1 expresses Bliss independence in
terms of growth costs, and also generalizes it to include
an S-dependent reduction of A to Aeff.T h e r e f o r e ,t h e
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http://www.biomedcentral.com/1752-0509/6/48Figure 1 Single and Multiple Drug Growth Costs. a. Growth cost is defined as the reduction in growth rate of cells treated with a drug relative
to the growth rate of untreated cells. Solid lines, best fits to Hill functions h(x)=x
n/(Ki
n+x
n), with Ki equal to the concentration of drug i (i=S for
salicylate, i=A for both antibiotics) at which growth is inhibited by 50%. KA=1.80 (1.66, 1.93) μg/mL, n=1.97 (1.67, 2.26) for chloramphenicol;
KA=0.41 (0.37, 0.45) μg/mL, n=1.90 (1.61, 2.19) for tetracycline; and KS=6.06 (5.50, 6.62) mM, n=1 for salicylate. 95% confidence intervals from
nonlinear least squares fitting in parentheses. Error bars are standard deviation of four replicates. b. In the presence of high concentrations of
chloramphenicol (Cm), growth is maximal for a nonzero concentration of salicylate (upper insets: OD time series). Contours of constant growth in
concentration space indicate suppression. Dashed line, contours of 45% and 55% maximum growth.
Wood and Cluzel BMC Systems Biology 2012, 6:48 Page 3 of 11
http://www.biomedcentral.com/1752-0509/6/48approximate additivity of drug costs implied by Bliss in-
dependence is modified to an approximate additivity of
effective costs (Figure 2a). The model assumes that the
presence of inducer reduces the effective concentration of
drug A and adds an additional cost, but otherwise does
not affect growth rate. This assumption considerably lim-
its the spectrum of possible cellular responses to the drug
pair, because drug S can only change the effective con-
centration of drug A, but will not change the shape of its
cost function. The model can be readily extended to
a
b
Figure 2 Cost-Benefit Model for Interactions between MAR inducers and Antibiotics. a. The combined growth cost of two drugs (S and A)
is assumed to be Bliss independent, as long as the effective concentration of one drug is reduced by the presence of the second drug. Thus, the
combined cost of both drugs is approximately equal to the sum of effective growth costs, f and g, for each individual drug. The reduction of each
drug's growth cost depends on the concentration of the other drug, which in turn dictates the growth benefit provided. b. mar promoter activity,
defined as the steady state time-averaged Fluorescence/OD times relative growth rate, increases as a function of salicylate concentration. Error
bars are +/− one estimated standard deviation. Inset: mar fluorescence concentration (YFP fluorescence/optical density) time series for
concentrations of salicylate ranging from 0 mM (purple) to 6 mM (blue). Data points are means over two replicates. Promoter activity is estimated
by averaging fluorescence concentration in the steady state and multiplying by relative growth rate.
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case S is also changed to Seff. However, because the anti-
biotics used are poor inducers of the MAR system
(Additional file 1: Figure S7), we neglect their effects on
the concentration S and limit this study to the direc-
tional model implied by Equation [1].
A simple model, which assumes that the concentra-
tion of antibiotic A is reduced by the induction of efflux
pumps (Additional file 1), suggests a form for Aeff:
Aeff ¼
A
1 þ β s ðÞ
ð2Þ
We call the function β(S) the inducible benefit, and
it contains all quantitative information about the re-
sistance mechanisms induced by drug S. To estimate
the inducible benefit, β(S), for the MAR system, we
measured the activity of the mar promoter as a func-
tion of S (Figure 2b; Additional file 1). MAR promoter
activity could dictate the functional form for β(S) if,
for example, we assume it is proportional to the
number of efflux pumps produced in response to sa-
licylate (Additional file 1). We scale this promoter
activity by an adjustable parameter βmax,s ot h a t
β S ðÞ   βmax S= Kind þ S ðÞ ,w h e r eK ind=0.8 is the con-
centration of inducer that yields half maximal promoter
activity (Figure 2b). The adjustable parameter βmax links
mar activity induced by drug S to a phenotypic response
(resistance) to a second drug A. This parameter will
be specific to drug A, and it provides a measure of
the efficiency with which MAR induction eliminates A
from the cell.
The cost-benefit theory assumes that the effects of
the inducing drug and the antibiotic are independent,
up to a reduction in the concentration of the antibiotic.
The aim of our model is not to achieve a microscopic
theoretical description of the system, but rather to pro-
vide a minimal phenomenological model that quantita-
tively captures the measured behavior. The success or
failure of the model must therefore be determined ex-
perimentally. Specifically, our model does not attempt
to elucidate the microscopic variables governing the
multi-drug effects—which would require dozens, if not
hundreds, of microscopic parameters—but rather posits
that a simple relationship should exist between cell
growth in the presence of one drug (which is a function
of the cell’s internal state) and cell growth in the pres-
ence of two drugs (which is a function of an entirely
different intracellular state). Specifically, the model
requires equality between cell growth in the presence
of A and cell growth in the presence of the com-
bination S and A' (with A'>A), once we account
for the costs of drug S. To directly verify this
hypothesis, we can rearrange equation 1 to express this
concept as
CSA   gS ðÞ
1   gS ðÞ
¼ fA eff

ð3Þ
The left hand side represents the "adjusted" multi-drug
cost, once the toxic effects of S (cost) have been
removed. The model implies that this adjusted cost of
the drug combination, as a function of Aeff, is function-
ally equivalent to the cost function f(x) for a single drug.
Hence, if one removes from the multi-drug costs (CSA)
the effects of g(S) according to the left-hand side of
Equation 3 and then properly chooses the concentration
reduction A!Aeff (determined by the single parameter
βmax), all two-drug data from a given drug combination
should collapse to the single curve determined by f(x).
Note that because a Hill function describes costs for
many individual drugs as well as slices through many
drug combination effect surfaces[10], collapsing the
multi-drug cost curves from a given drug pair (Figure 3a)
to a common Hill form can be simply achieved using in-
dependent parameters for each salicylate concentration.
By contrast, equation 3 suggests that a non-trivial col-
lapse of all curves for a given drug pair requires only a
single parameter βmax. Once this parameter is deter-
mined, the beneficial effects of different concentrations
of salicylate are linked by the mar promoter activity
curve. We verified this constraint (Figure 3b) by fitting
the single free parameter, βmax, using two-drug cost curves
for salicylate and chloramphenicol (βmax=1.15 +/− 0.15)
and salicylate and tetracycline (βmax=6.04+/− 0.16). In all
cases, the model provides an excellent fit to the data
(R
2=0.98; see Additional file 1: Figure S2 for a direct com-
parison of growth rates from experiment and model).
Interestingly, this analysis demonstrates that a superpos-
ition of cost and benefit functions quantitatively describes
the combined effects of salicylate and an antibiotic. Sur-
prisingly, we find that the benefit function depends only
on the inducer concentration and is dictated by the mar
induction curve.
Transition from salicylate as toxic to salicylate as
beneficial
Our results uncover an interesting range of cellular be-
havior that emerges from the trade-offs of salicylate
toxicity and the simultaneous induction of multi-drug
resistance. First, for each concentration of antibiotic, we
find that growth is maximal at a single salicylate con-
centration S*. In addition, we see an apparent transition
between two regimes—one where the presence of the
inducing drug is harmful, and another where it is bene-
ficial—as A eclipses a threshold Acrit (Figure 4a). That
is, S* becomes non-zero as A crosses Acrit. In other
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but only when the antibiotic environment is sufficiently
toxic to offset the inherent toxicity of the inducer.
Interestingly, we find that mar promoter activity satu-
rates at S 4 mM (Figure 2b), which is greater than S*
for all concentrations of antibiotics used. Therefore,
maximum suppression at S* results from a non-trivial
interplay between MAR expression and inducer cost,
not merely a maximum in MAR expression.
Contributions of inducer cost and benefit to apparent
MIC’s of antibiotics
Given our characterization of salicylate-induced multi-
drug resistance, it is straightforward to calculate the ap-
parent MIC of an antibiotic in the presence of any con-
centration of salicylate. Here, we define the apparent
MIC to be the minimum concentration of drug A at
which relative growth is reduced to a value of δ. For
small concentrations of salicylate, the apparent MIC’so f
both tetracycline and chloramphenicol increase dramat-
ically (Figure 4b). However, at higher concentrations,
the toxicity of salicylate begins to overwhelm its poten-
tial benefits, eventually leading to a decrease in appar-
ent MIC. It is therefore clear that MIC reflects
contributions of both the cost and benefits of the indu-
cing drug. By contrast, the interdependence of inducible
resistance and mar promoter activity can be described
using only a single parameter, βmax, which provides a
quantitative measure of inducible benefit that is not
masked by the effects of inducer cost.
Phase diagram for MAR-mediated drug interactions
The interactions between salicylate and tetracycline, sali-
cylate and chloramphenicol, and sodium benzoate and
tetracycline are all suppressive, but this class of models
describes a range of interactions ranging from synergistic
to suppressive, based on the interplay of induction bene-
fit and drug toxicity. Using Equations 1 and 2, we
Figure 3 Cost-Benefit Analysis Quantitatively Describes Multi-Drug Growth Cost Functions. a. Multi-drug growth cost curves for salicylate
and tetracycline (top) and salicylate and chloramphenicol (bottom) are increasing functions of antibiotic concentration, but also depend on the
concentration of salicylate. Each growth cost curve represents growth in increasing concentrations of antibiotic at a single salicylate
concentration, ranging from 0 to 7 mM. Black lines, ([salicylate]=0 mM), which correspond to the single drug growth cost functions. Data points,
means of four replicates. Error bars, +/− one sample standard deviation. b. The cost-benefit model requires rescaled versions of the multi-drug
cost functions to have the same mathematical form as single drug cost functions (Equation 3). To directly test this assumption, we rescaled the
multi-drug cost functions in panel a by removing the contribution from salicylate toxicity (cost) to each multi-drug growth cost function. Then,
we rescaled the concentration of each antibiotic (chloramphenicol or tetracycline) using the single parameter βmax, which accounts for the
salicylate-induced reduction of intracellular antibiotic concentration (benefit). We trivially exploit the common Hill form of the single drug costs
functions to show data from both drug pairs on a single plot, achieved by replacing drug concentration with effective toxicity, defined as ([A]/KA)
n,
where KA and n characterize the single drug growth cost function for the antibiotics (see Figure 1). We use the salicylate induction curve of the mar
promoter (Figure 2b) as the benefit function β(S), for both drug interactions, with only the overall scale of the benefit function (βmax) specific to the
two antibiotics. See also Additional file 1: Figure S2 for a direct comparison of growth rates from experiments and models.
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maximal depends on the external concentration of antibiotic. A transition occurs between the low antibiotic regime, where the presence of
salicylate is harmful, to the high antibiotic where the presence of salicylate increases the growth of cells. Red, tetracylcline; Blue, chloramphenicol.
Concentrations for both drugs measured in μg/mL. Curves, numerical calculation from model; circles, estimates of S* from experiments at single
concentrations of A. Maxima were estimated using cubic spline interpolation between data points at different concentrations of salcilyate. Error
bars, concentrations corresponding to +/− 1% of maximum. b. Apparent MIC, defined as the minimum concentration of antibiotic (red,
tetracycline; blue, chloramphenicol; both in units of μg/mL) at which growth is reduced to δ=0.5. While the quantitative results depend on the
precise definition of MIC, the qualitative features do not depend on the choice of δ. c. Cost-benefit theory predicts general properties of drug
interactions as a function of the maximum inducible benefit βmax and the concentration of inducer, S. Solid line, phase boundary between
synergistic and antagonistic drug interactions. Dashed line, phase boundary between antagonistic and suppressive interactions. In general, a
higher value of the βmax increases the antagonism between drug pairs at a given concentration of drug S. Parameters characterizing individual
drugs include KS and Kind, which characterize, respectively, the cost of drug S and the corresponding induction of resistance systems (e.g. efflux
pumps), and KA and n, which characterize the cost of drug A. By contrast, βmax couples the individual effects of two drugs. Insets, heat maps of
two-dimensional growth surfaces for 3 cell strains in the presence of Salicylate (Sal) and Chloramphenicol (Cm); top: βmax=1.15 (WT cells;
suppressive), βmax=0.19 (mar mutant, antagonistic), and βmax=−0.15 (tolC mutant, synergistic). See also Additional file 1: Figure S3.
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itional file 1: Figure S3) that specifies how a drug inter-
action depends on the trade-offs between inducible
benefit (described by the parameters Kind and βmax), the
cost of inducer (KS), and the steepness of the antibiotic
dose-response curve (n). Specifically, the cellular re-
sponse to the first drug (S) alone includes both the
growth cost of the drug (characterized by KS) and the in-
duction of MAR system (characterized by Kind). The dy-
namics of the efflux pumps and their specificity for drug
A determine the concentration reduction (A to Aeff),
which is governed by βmax. The phase diagram demon-
strates that properties of the drugs alone (n, KS,K ind) de-
termine the level of drug coupling, contained in βmax,
required to achieve antagonism or suppression. Drugs
that strongly induce growth benefit and have low asso-
ciated cost (Kind<<KS) are always suppressive. By con-
trast, high cost inducers (Kind >>KS) can never be
suppressive because the cost of induction is too high
(Figure 4c).
The inducible benefit parameter (βmax=1.15) charac-
terizing the salicylate and chloramphenicol combination
in wild type cells is far above the suppressive-antagonis-
tic boundary (βmax >>2Kind/(K1n)=0.45), and the inter-
action is clearly suppressive for all concentrations of
salicylate. To explore different regions of the phase dia-
gram experimentally, we measured the effects of two dif-
ferent mutations on the suppressive drug interaction
between salicylate and chloramphenicol. The first mu-
tant, ΔtolC [31], lacks the protein TolC required for ef-
flux pumping [32]. While we expect that the ΔtolC
deletion will partially suppress the benefit induced by sa-
licylate, we cannot predict how the costs of the drugs
and, therefore, the precise nature of the drug interaction,
will be altered. Experimentally, this mutant showed
decreased resistance to chloramphenicol (Figure 4a, 4b),
corresponding to a rescaling of the single drug cost (i.e.
KA smaller than in wild type), but the cost of salicylate
remains unchanged (KS approximately same as wild
type). βmax was measured to be −0.15 +/− 0.01. Accord-
ing to the phase diagram (Figure 4), the interaction
should therefore be weakly synergistic, and in fact the
contours of constant growth appear slightly concave
(lower inset). The suppressive drug interaction has been
eliminated because the benefit associated with salicylate
has been decreased while its cost remains unchanged,
resulting in significantly less antagonistic interaction.
Since the suppressive interaction between salicylate
and chloramphenicol is partially associated with the syn-
thesis of AcrAB-TolC efflux pumps, we also hypothe-
sized that cells with constitutive mar promoter activity
would disrupt the cost-benefit interplay required for
drug suppression. We selected such a mutant, here-
called a tet mutant, by growing cells in 1 μg/mL
tetracycline for 48 hours. We observed that the MAR
system is a common target for mutations that confer re-
sistance to tetracycline (see also [23]) (Additional file 1:
Figure S6). In terms of our cost-benefit analysis, these cells
synthesize resistance systems (benefit) without the asso-
ciated cost of an inducing drug. To verify the molecular
basis of resistance in the tet mutant, we sequenced the full
genome and found only a single point mutation in the α5
region of the MAR repressor marR, which is linked to
dimer formation and subsequent binding to the mar pro-
moter [33]. In the salicylate-chloramphenicol combination,
the tet mutant showed increased resistance to chloram-
phenicol (KA is larger than in wild-type) and a near-addi-
tive drug interaction (βmax=0.19 +/− 0.03) between
salicylate and chloramphenicol (Figure 4). Because the cost
of salicylate is unchanged, the elimination of suppression
suggests that the mutation has blocked the inducible bene-
fit of salicylate (see also Additional file 1: Figure S5 for
similar results with a different drug pair). Biologically, the
inactivation of the MarR repressor no longer requires the
presence of salicylate, and therefore the cost of the drug
exceeds its associated inducible benefit. Interestingly, we
also found that the mar activity in the mutant is higher in
the absence of salicylate than the maximum mar activity
induced by even high concentrations of salicylate in the
wild type strain. However, adding salicylate further
increases mar activity in the mutant (Additional file 1:
Figure S7A). Moreover, the functional dependence of
the induction on salicylate is similar to that of the wild-
type (Additional file 1: Figure S7A, inset). This result is
not intuitive because the beneficial effects of salicylate
on the growth of the mutant in the presence of chloram-
phenicol are quite small (βmax is approximately 17% of
that of the wild type, and the antagonism between the
drugs is markedly decreased).
Discussion
Efflux is a widespread cellular defense mechanism with
clinical consequences for antimicrobial treatments. Cost-
benefit principles provide a convenient tool for analyzing
these ubiquitous systems. We have shown that such a
framework provides a quantitative description of drug
interactions associated with the classic MAR system,
which mediates an inducible resistance to many different
toxic agents. The model allows us to quantify the relative
importance of the induction mediating reversible resist-
ance and the toxicity of the inducing agent. In particular,
we observe a transition between two regimes, one where
salicylate is harmful and one where it is beneficial, as the
concentration of antibiotic crosses a threshold Acrit.B y
disentangling the contributions of inducer cost and
benefit, the analysis also provides a quantitative measure
(βmax) of the reversible (MAR-mediated) resistance to
each antibiotic used. This measure complements
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mation about the net effect of both inducer costs and
benefits but that mask the relative contributions of each.
We demonstrate that it is precisely this balance between
cost and benefit that determines whether the antimicro-
bial properties of multiple agents are synergistic, antag-
onistic, or suppressive. Therefore, in addition to
providing a new quantitative model of the MAR system,
we also lay the groundwork for a link between the short-
term trade-offs of inducible resistance, which determine
the type of interaction between pairs of toxic agents, and
the acquisition of irreversible resistance mediated by
these drug interactions.
This framework may be applicable to other systems
where environmental signals can be toxic but also induce
transient resistance. For example, cancer cells can acti-
vate pro-survival stress responses upon treatment with
chemotherapies or radiation[34], and subpopulations of
tumor cells can access new transcriptional/differenti-
ation states to become reversibly drug resistant[35]. Our
analysis implements efflux-mediated resistance using a
concentration reduction A ! Aeff for the effective con-
centration of drug A, and this form could be used to de-
scribe other common mechanisms of resistance,
including enzymatic decay and target modification. As a
consequence, the cost-benefit framework developed here
may prove useful for modeling and understanding a wide
range of systems governed by the inherent trade-offs of
inducible resistance.
Conclusions
Our analysis provides a quantitative description of the
MAR system and demonstrates that optimal cell growth
in the presence of an inducer and an antibiotic does not
coincide with maximum induction of the mar promoter,
but instead results from the interplay between drug tox-
icity and mar induction. In addition, we show that this
interplay determines whether the drugs are synergistic,
antagonistic, or suppressive. The framework may also be
extensible to more general systems where combinations
of environmental cues contribute to both transient resist-
ance and toxicity.
Methods
Strains
We used the E. coli Frag-1B strain, which is wild-type for
the AcrAB multiple drug efflux pump system, and also
the wild-type E.coli BW25113 strain. The ΔtolC mutant
is strain JW5503-1 from the Keio collection.
Drugs
Drug solutions were made from solid stocks (sodium sa-
licylate, Sigma-Aldrich; chloramphenicol, MP Biomedi-
cals; tetracycline hydrochloride, Acros Organics;
doxycycline hyclate, Sigma- Alderich; kanamycin, Fisher;
ciprofloxacin, Sigma-Alderich). All antibiotic stock solu-
tions were stored in the dark at −20°C. All drugs were
thawed (when necessary) and diluted in sterilized Lennox
LB broth (Fisher) for experimental use.
Growth conditions and drug treatments
We inoculated LB media with a single colony and grew
the cells overnight (12 h at 30°C with shaking at
200 rpm). Following overnight growth, stationary phase
cells were diluted (600–1000 fold) in LB media contain-
ing 0.2% glucose and grown for an additional 3 h (30°C
with shaking at 200 rpm). Following the initial dilution
period, we transferred cells to 96 well microplates (round
bottom, polystyrene, Corning) and set up a two-dimen-
sional matrix of drug concentrations in each 96-well
microplate (165 μl media per well). For the remainder of
the experiment (4–8 h), cells were grown at 30°C with
shaking at 1200 rpm on a Heidolph Titramax vibrating
microplate shaker (Brinkmann). Plates were wrapped in
aluminum foil to minimize evaporation. A600 (absorbance
at 600 nm, proportional to optical density OD) and YFP
fluorescence were measured at 15–25 min intervals for
4–8 h using a Wallac Victor-2 1420 Multilabel Counter
(PerkinElmer).
Growth rate estimation and MIC determination
Growth rates were determined by fitting multiple regions
of growth curves (A600 vs. time, Additional file 1: Figure
S4) in early exponential phase to an exponential function
(MATLAB 7.6.0 curve fitting toolbox, The Mathworks)
using a variable length (45–150 minutes) sliding window.
Growth rate corresponded to the window position asso-
ciated with best fit to an exponential function, determined
by a minimum root mean squared error (RMSE). For each
experimental condition, the final growth rate was the sam-
ple mean of 4 replicates (See also Additional file 1).
Growth rate contours were estimated from experimental
data using the Matlab csaps function to interpolate be-
tween data points (typically 96) spaced roughly evenly
throughout the two dimensional space of drug con-
centrations. MIC was taken to be the drug concentra-
tion(s) at which growth was inhibited by 50%.
Drug resistant mutants
We diluted liquid cultures of wild-type cells (in station-
ary phase) 1000-fold into 96 individual 150 μL cultures
on a single microplate, with each well supplemented with
1.0 μg/mL tetracycline. After approximately 48 h of
growth at 30°C with shaking, optical density and fluores-
cence were measured from each well. Samples from ran-
domly selected cultures exhibiting high OD and
fluorescence (Additional file 1: Figure S6) were frozen in
15% glycerol at −80°C. Frozen cultures were used to
Wood and Cluzel BMC Systems Biology 2012, 6:48 Page 9 of 11
http://www.biomedcentral.com/1752-0509/6/48streak LB plates, and all experiments (including sequen-
cing) were performed on cultures grown from a single
colony isolated from these plates.
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and Supplemental Notes [10,23,36-42].
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